DFM Funding Monitor

Vascularized Next-Generation Tumor-on-Chip for ADC Global Evaluationbroad

VANTAGE · Horizon Europe grant · 2026-09-01–2027-05-31

EC contribution

€300,000

Total cost

€0

Beneficiaries

1

About the data

Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2026-AIC · scheme HORIZON-EIC · topic HORIZON-EIC-2026-AIC-02. CORDIS record →

Objective

Objectives: The project aims to industrialize a human vascularized tumor-on-chip (VANTAGE) to bridge the ""predictive gap"" in Antibody-Drug Conjugate (ADC) development. Primary goals include: (1) Quantifying the ""total spectrum"" of ADC efficacy, from primary tumor regression to the inhibition of micrometastatic seeds

Beneficiaries (1)

Organisation	Country	Role	EC contribution	SME
UNIVERSITAET BERN	CH	coordinator	€300,000

Get the EU Defence Funding Calendar — free

The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.

Get the calendar

Yes — subscribe me to DFM Analysis, the free weekly briefing on European defence funding, and send me the monthly funding calendar. Unsubscribe anytime.

Website

We store your email to send the calendar and the weekly DFM Analysis briefing. Nothing else. Unsubscribe anytime.

Or browse all open defence & dual-use calls on the funding calendar →

Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.